SPONSOR
Alexion Pharmaceuticals, Inc.
Total Trials
6
Recruiting
6
Phases
Phase 3, Phase 1, Phase 2
Conditions studied: NMOSDNeuromyelitis Optica Spectrum DisorderGeneralized Myasthenia GravisBAG3 Mutation Associated Dilated CardiomyopathyIgANIgAVNImmunoglobulin A NephropathyImmunoglobulin A Vasculitis Associated NephritisHenoch-schonlein Purpura NephritisIgA Vasculitis
Alexion Pharmaceuticals, Inc. is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including NMOSD, Neuromyelitis Optica Spectrum Disorder, Generalized Myasthenia Gravis, BAG3 Mutation Associated Dilated Cardiomyopathy.
The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Alexion Pharmaceuticals, Inc.
How many clinical trials has Alexion Pharmaceuticals, Inc. sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by Alexion Pharmaceuticals, Inc., of which 6 are actively recruiting participants. These trials cover conditions including NMOSD, Neuromyelitis Optica Spectrum Disorder, Generalized Myasthenia Gravis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Alexion Pharmaceuticals, Inc. research focus on?
Alexion Pharmaceuticals, Inc. clinical trials span NMOSD, Neuromyelitis Optica Spectrum Disorder, Generalized Myasthenia Gravis, BAG3 Mutation Associated Dilated Cardiomyopathy, IgAN, and additional conditions. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Alexion Pharmaceuticals, Inc. clinical trial?
To participate in a Alexion Pharmaceuticals, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Alexion Pharmaceuticals, Inc. trials with current recruitment status updated daily.
Clinical Trials by Alexion Pharmaceuticals, Inc.
NCT07557420 Phase 3
Recruiting
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD
NCT04202341
Recruiting
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Generalized Myasthenia Gravis
NCT07218887 Phase 1, Phase 2
Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
BAG3 Mutation Associated Dilated Cardiomyopathy
NCT07024563 Phase 3
Recruiting
Study of Ravulizumab in Pediatric Participants With Primary IgAN
IgAN
NCT06830798 Phase 3
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Delayed Graft Function
NCT07081646 Phase 1, Phase 2
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Relapsed AL Amyloidosis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology